Suppr超能文献

重型地中海贫血患者经过24至36个月的强化螯合治疗后葡萄糖代谢紊乱情况得到改善。

Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.

作者信息

Platis Odysseas, Anagnostopoulos Georgios, Farmaki Kallisteni, Posantzis Markos, Gotsis Efstathios, Tolis Georgios

机构信息

Thalassaemia Unit, General Hospital of Corinth, 53, Athens Avenue, 20100 Corinth, Greece.

出版信息

Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:279-81.

Abstract

Thalassaemic patients with haemocromatosis often present with metabolic disturbances such as diabetes mellitus. A group of adult thalassaemic patients who received intensive oral and subcutaneous chelation therapy (Defferiprone/Ferriprox and Desferioxamine/Desferal) for a period of 24-36 months was studied for the presence of glucose metabolism disturbances (GMD). Investigation of the prevalence of diabetes mellitus (DM) and impaired glucose tolerance (IGT) was carried out by yearly oral glucose tolerance tests (OGTT). Results showed that GMD (DM and IGT) improved in 1/3 of the patients after the intensive combined chelation treatment, a finding that we attributed to a reduction in liver iron deposits. Although this study is still in progress we believe that intensive combined chelation therapy may have a positive effect on glucose metabolism.

摘要

患有血色素沉着症的地中海贫血患者常出现如糖尿病等代谢紊乱。对一组接受了24至36个月强化口服和皮下螯合疗法(去铁酮/铁普罗克斯和去铁胺/地拉罗司)的成年地中海贫血患者进行了葡萄糖代谢紊乱(GMD)情况研究。通过每年的口服葡萄糖耐量试验(OGTT)来调查糖尿病(DM)和糖耐量受损(IGT)的患病率。结果显示,强化联合螯合治疗后,三分之一的患者葡萄糖代谢紊乱(糖尿病和糖耐量受损)情况有所改善,我们将这一发现归因于肝脏铁沉积的减少。尽管这项研究仍在进行中,但我们认为强化联合螯合疗法可能对葡萄糖代谢有积极影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验